Riley Kandel

Pembrolizumab in the adjuvant setting yielded high DFS and OS results in addition to a manageable safety profile in real-world patients with ccRCC.

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

BTK and PI3K inhibition produced responses but unexpected PK data in relapsed/refractory PCNSL.

NICE has recommended obecabtegene autoleucel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

OBI-902 received orphan drug designation from the FDA for the treatment of patients with cholangiocarcinoma.

Andrew Yee, MD, discusses data for a modified four-drug regimen studied in older patients with newly diagnosed multiple myeloma.

ZEN-3694 obtained orphan drug designation from the FDA for the treatment of NUT carcinoma.

Scott Tagawa, MD, MS, FACP, FASCO, discusses data for lutetium Lu 177 vipivotide tetraxetan in mHSPC from the PSMAddition trial.